FIELD: medicine, pharmaceutics.SUBSTANCE: invention describes compounds of formula (I) wherein: R1 means C1-6alkyl or C3-6cycloalkyl； wherein R1 may be optionally carbon-substituted by one or more R6； R2 means hydrogen； R3 and R4 are carbon substitutes, and each is independently specified in carboxy, carbamoyl, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, N-(C1-6alkoxy)carbamoyl, phenyl-R9 - or heterocyclyl-R10-； wherein R3 and R4 may be independently carbon-substituted by one or more R11； and wherein provided said heterocyclyl contains -NH - residue, then nitrogen may be optionally substituted by a group specified in R12； m has the value of 0, 1 or 2； wherein the values R3 may be equal or different； p has the value of 0, 1 or 2； wherein the values R4 may be equal or different； the ring A means nitrogen-containing 5- or 6-member heterocyclic group； wherein drawn nitrogen represents = N- and is found in an ortho-position to R1R2NC(O)NH group in formula (I)； the ring B means phenyl or heterocyclyl； wherein provided said heterocyclyl contains -NH- residue, then nitrogen may be optionally substituted by a group specified in R14； R5 is specified in hydroxy, C1-6alkoxy or -N(R15)(R16)； R6 and R11 are carbon substitutes and each is independently specified in halo, C1-6alkyl or C1-6alkoxy； R15 and R16 are independently specified in hydrogen, C1-6alkyl, C1-6alkoxy, cyclopropyl or cyclopentyl； R12 and R14 mean C1-6alkyl； wherein R14 may be optionally carbon specified by one or more R23； R9 and R10 mean a direct link； and R23 means halo or methoxy； wherein said heterocyclyl means pyridine, imidazole, triazole, thiazole, benzothiazole, imodazolepyridine, dihydroquinoline or thiadiazole, or its pharmaceutically acceptable salt； provided said compound represents other than ethyl ester of 5-[2-[[(ethylamino)carbonyl]amino]pyridin-4-yl]-4-methyl-4H-1,2,4-triazole-3-carboxylic acid or their pharmaceutically accepta
